Rifaximin Polymorph Crystallization Process
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The existing production methods for rifaximin lack standardization in achieving homogeneous polymorphs, leading to variations in bioavailability, solubility, and stability, which affect pharmacological and toxicological properties, and may induce bacterial resistance due to uncontrolled systemic absorption.
Innovation Solution
The process involves reacting rifamycin ο with 2-amino-4-methylpyridine in a solvent mixture of water and ethyl alcohol, followed by specific temperature and time controls during crystallization and drying to produce distinct polymorphs rifaximin δ and ε, which differ in water content and absorption profiles, allowing for modulation of systemic absorption and reduced resistance induction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If generic crystallization and drying methods are used, then production simplicity is maintained, but polymorph homogeneity and pharmacological consistency deteriorate
Solution Approach 1:
The patent applies parameter changes by establishing specific crystallization temperature ranges (0°C to 25°C) and drying conditions (temperature and humidity control) to obtain consistent polymorph forms. These controlled parameters ensure homogeneous rifaximin polymorphs while maintaining practical manufacturability, resolving the contradiction between process simplicity and polymorph consistency.
Solution Approach 2:
The patent employs preliminary action by pre-defining optimal crystallization and drying conditions before production. The specified temperature ranges and humidity levels are determined in advance to ensure that the desired polymorph forms are obtained consistently, eliminating the need for post-production polymorph control and simplifying the overall manufacturing process.
2Adaptability or versatility
If crystallization conditions are not controlled, then production flexibility is maintained, but bioavailability and solubility consistency deteriorate
Solution Approach 1:
The patent maintains production flexibility while ensuring bioavailability consistency by specifying parameter ranges rather than fixed values. The crystallization temperature range (0°C to 25°C) and controlled drying conditions allow manufacturers to adapt to different production environments while guaranteeing consistent polymorph formation, which directly determines reliable bioavailability and solubility characteristics.
3Adaptability or versatility
If polymorph forms are not standardized, then manufacturing adaptability is maintained, but pharmacological and toxicological properties deteriorate
Solution Approach 1:
The patent standardizes polymorph forms through controlled parameter changes during crystallization and drying, ensuring consistent pharmacological and toxicological properties. By defining specific temperature and humidity ranges, the patent achieves manufacturing adaptability within a standardized framework, guaranteeing reliable drug performance across different production batches.
4Ease of manufacture
If drying conditions are not optimized, then process simplicity is maintained, but water content and polymorph form control deteriorate
Solution Approach 1:
The patent optimizes drying conditions by controlling temperature and humidity parameters to achieve precise water content levels (0.5-5.0% w/w). This controlled approach maintains relative process simplicity while ensuring consistent polymorph formation and water content, resolving the contradiction between ease of manufacture and manufacturing precision.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process ensures the production of pure, homogeneous rifaximin polymorphs with controlled bioavailability and reduced systemic absorption, enhancing pharmacological efficacy and minimizing resistance risks, thereby improving the manufacturing efficiency and safety of medicinal preparations.
Implementation Method 1
the crystallization can be carried out in suitable solvents or solvent systems
Implementation Method 2
dried both under atmospheric pressure and under vacuum
Data Source
AI summary
Crystalline polymorphous forms of the rifaximin (INN) antibiotic named rifaximin δ and rifaximin ε useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.